Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D017277:Drug Approval; D004348:Drug Labeling; D005260:Female; D006801:Humans; D007155:Immunologic Factors; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D042461:Vascular Endothelial Growth Factor A